Lindbrook Capital, LLC - ADAPTIMMUNE THERAPEUTICS PLC ownership

ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 93 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q3 2021. The put-call ratio across all filers is 3.27 and the average weighting 0.1%.

Quarter-by-quarter ownership
Lindbrook Capital, LLC ownership history of ADAPTIMMUNE THERAPEUTICS PLC
ValueSharesWeighting
Q3 2023$3,596
-15.7%
4,6100.0%0.00%
Q2 2023$4,264
+42.1%
4,610
+49.5%
0.00%
-100.0%
Q3 2022$3,000
+200.0%
3,084
+869.8%
0.00%
Q2 2022$1,000318
+77.7%
0.00%
Q1 2022$0
-100.0%
179
-94.5%
0.00%
-100.0%
Q4 2021$12,000
-73.3%
3,275
-62.2%
0.00%
-83.3%
Q3 2021$45,000
+60.7%
8,667
+31.1%
0.01%
+100.0%
Q2 2021$28,000
+211.1%
6,610
+310.6%
0.01%
+200.0%
Q1 2021$9,0000.0%1,6100.0%0.00%0.0%
Q4 2020$9,000
-30.8%
1,6100.0%0.00%
-50.0%
Q3 2020$13,000
-68.3%
1,610
-60.3%
0.00%
-66.7%
Q2 2020$41,000
+1266.7%
4,058
+332.6%
0.01%
+1100.0%
Q1 2020$3,0009380.00%
Other shareholders
ADAPTIMMUNE THERAPEUTICS PLC shareholders Q3 2021
NameSharesValueWeighting ↓
MPM ASSET MANAGEMENT LLC 6,287,101$4,903,9392.63%
Syncona Portfolio Ltd 1,377,294$1,074,2891.60%
MPM BioImpact LLC 5,095,912$3,974,8111.06%
NEA Management Company, LLC 17,079,778$13,322,2271.03%
TANG CAPITAL MANAGEMENT LLC 5,166,954$4,030,2240.57%
PFM Health Sciences, LP 10,423,135$8,130,0450.38%
Matrix Capital Management Company, LP 38,974,185$30,399,8640.36%
Long Focus Capital Management, LLC 10,963,158$8,551,2630.31%
Acuitas Investments, LLC 479,764$374,2160.22%
Endurant Capital Management LP 311,944$243,3160.22%
View complete list of ADAPTIMMUNE THERAPEUTICS PLC shareholders